Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 08 of 110 Updated Nov 17, 2026

Orforglipron

LY3502970 · OWL833

PHASE 3 · ORAL NON-PEPTIDE GLP-1 AGONIST

▓ 197 indexed citations across PubMed (131), ClinicalTrials.gov (54), EuropePMC (12).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

197 citations across 8 tiers

Tap any tier to jump to that section of the bibliography.

Background

Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.

→ Wikipedia

Mechanism of action

Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment 14

Researched effects

Weight loss 11.2% at 72 weeks (ATTAIN-1, n=3,127) 16; 11.1% and 9.6% at the 17.2 mg label maximum in the two registration trials, 9.0 and 7.1 points over placebo 15; HbA1c reduction ~1.5 points in early type 2 diabetes (ACHIEVE-1, n=559) 17; oral once daily

Reported efficacy (trial readout)

  • Weight Loss 11.2%

    NEJM (Phase 3, 72wk, n=3,127)

    High confidencen=3,127Phase 32025
  • Hba1c Reduction 1.5%

    NEJM (Phase 3, 40wk, n=559)

    High confidencen=559Phase 32025

Trial-efficacy data current as of November 16, 2026.

Live evidence

FDA label safety

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology ( 13.1 )] . While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (…

Contraindications

4 CONTRAINDICATIONS FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.2 )] . Personal or family history of MTC or in patients with MEN 2 ( 4 ) Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO ( 4 )

Full FDA label (DailyMed) →

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) 15

→ FDA FOUNDAYO (orforglipron) prescribing information (starting dose and escalation schedule)

Known concerns

GI effects; hepatic enzyme elevations

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.

    Cardiovascular diabetology. Endocrinology reports · 2026 — META-ANALYSES · AUTHORITY 94.5

  2. Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.

    Acta diabetologica · 2026 — META-ANALYSES · AUTHORITY 94.5

  3. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.

    European journal of medical research · 2026 — META-ANALYSES · AUTHORITY 94.5

  4. The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.

    Endocrinology, diabetes & metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

  5. Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.

    Diabetes technology & therapeutics · 2026 — META-ANALYSES · AUTHORITY 94.5

  6. Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.

    Diabetes, obesity & metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

  7. The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.

    2026 — META-ANALYSES · AUTHORITY 94.5

  8. Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.

    Endocrinology, diabetes & metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

  9. Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 — META-ANALYSES · AUTHORITY 94.5

  10. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

    BMJ (Clinical research ed.) · 2026 — META-ANALYSES · AUTHORITY 94.5

Full citation library

Year distribution

Meta-Analyses

28
  1. 1.

    Dutta D, Nagendra L, Anne B, Kumar M, et al. · Obesity science & practice · 2024 · PMID 38414573

    Orforglipron is a novel once-daily oral non-peptide glucagon-like peptide-1 receptor agonist with several recently published randomized controlled trials (RCTs) evaluating its role in diabetes and obesity. No meta-analysis has analyzed the efficacy and safety of orforglipron; this meta-analysis aimed to address this knowledge gap. A systematic search was conducted in electronic databases to identify RCTs that included individuals with obesity who were administered orforglipron and compared to ei…

  2. 2.

    Xie Z, Zheng G, Liang Z, Li M, et al. · Metabolism: clinical and experimental · 2024 · PMID 39305981

    This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tirzepatide, 15 or 10 mg; liraglutide,…

  3. 3.

    Nong K, Jeppesen BT, Shi Q, Agoritsas T, et al. · BMJ (Clinical research ed.) · 2025 · PMID 40813122

    To provide up-to-date evidence on key benefits, harms, and uncertainties regarding medications for adults with type 2 diabetes. Living systematic review and network meta-analysis (NMA), using frequentist random effects and GRADE (grading of recommendations, assessment, development and evaluation) approaches. Updates are planned at least two times a year. Medline and Embase, searched up to 31 July 2024 for the current iteration. Randomised controlled trials of at least 24 weeks comparing one or m…

  4. 4.

    Karakasis P, Patoulias D, Pamporis K, Stachteas P, et al. · Metabolism: clinical and experimental · 2023 · PMID 37852529

    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatment of type 2 diabetes mellitus (T2DM), obesity or both. Literature search was performed through Medline (via PubMed), Cochrane Library and Scopus until August 16, 2023. Double-independent study selecti…

  5. 5.

    Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, et al. · Archives of endocrinology and metabolism · 2024 · PMID 39420937

    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) or risk differences for binary endpoints wer…

  6. 6.

    An X, Sun W, Wen Z, Duan L, et al. · Diabetes, obesity & metabolism · 2025 · PMID 39910752

    This study aims to systematically evaluate and perform a systematic review and network meta-analysis comparing the comprehensive cardiovascular protective effects of various glucagon-like peptide-1 receptor agonists (GLP-1RAs), focusing on cardiovascular events and risk factors. We searched PubMed, Embase, Cochrane Library and Web of Science from inception to December 15, 2024. Included studies were published randomized controlled trials (RCTs) comparing GLP-1RAs to placebo or other GLP-1RAs. Mi…

  7. 7.

    Ismaiel A, Scarlata GGM, Boitos I, Leucuta DC, et al. · International journal of obesity (2005) · 2025 · PMID 40804463

    Overweight and obesity are major global health issues, increasing disease risk and straining healthcare systems. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss but cause gastrointestinal side effects, affecting adherence. Research often focuses on diabetics, leaving a gap in understanding their effects on non-diabetic individuals with overweight or obesity. This systematic review and dose-response network meta-analysis addresses this gap, analyzing gastrointe…

  8. 8.

    Bhattarai HB, Paudel BS, Parajuli SR, Dahal K, et al. · Medicine · 2025 · PMID 41465949

    Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. We performed a systematic review of the literature databases like PubMed,…

  9. 9.

    Guo H, Yang J, Huang J, Xu L, et al. · Obesity pillars · 2025 · PMID 39980735

    Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical trials of GLP-1/GIP/glucagon(GCG) triple agonists are ongoing. This study compared the efficacy and safety profiles of different GLP-1 receptor agonists (GLP-1RAs) for weight reduction and explored the related influencing factors, providing quantitat…

  10. 10.

    Pandey RK, Jan M, Mohammad A, Jawaid KA, et al. · Endocrinology, diabetes & metabolism · 2025 · PMID 41296780

    Obesity represents a major global health challenge, contributing substantially to cardiovascular disease and metabolic complications. Orforglipron, a novel oral non-peptide GLP-1 receptor agonist, has emerged as a promising therapeutic option for weight management and glycemic control. This meta-analysis evaluated the efficacy and safety of orforglipron in obese patients with or without type 2 diabetes mellitus (T2DM). A comprehensive literature search was conducted across PubMed, Embase, Cochra…

  11. 11.

    Zhou J, Wang F, Li S · Frontiers in endocrinology · 2025 · PMID 41450584

    This study assesses the efficacy and safety of the novel oral small molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) danuglipron and orforglipron in the treatment of type 2 diabetes (T2DM) and obesity through systematic review and meta-analysis. Electronic databases (PubMed, Web of Science, Cochrane Library and Embase) were systematically searched up to 20 May 2025 to include randomised controlled trials evaluating danuglipron/orforglipron in patients with T2DM and/or obesity. Chan…

  12. 12.

    Tantoush M, Almaghrabi Y, Abusbaeh A, Ahmed N, et al. · Cureus · 2026 · PMID 41728423

    Type 2 diabetes mellitus (T2DM) and obesity represent major global health challenges. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective treatments for both conditions, providing significant glycemic control and weight-reduction benefits. Orforglipron is an investigational, oral, non-peptide GLP-1RA that does not require complex absorption enhancers or dosing restrictions. Preclinical and early clinical studies have demonstrated promising results in glycemic control a…

  13. 13.

    Alper A, Peleg G, Fagin A, Shah P, et al. · Cardiovascular diabetology. Endocrinology reports · 2026 · PMID 41715239

    Obesity and type 2 diabetes are the primary drivers of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death worldwide. Injectable GLP-1 receptor agonists reduce major adverse cardiovascular events. Yet for many individuals, injection hesitancy remains a significant barrier to long-term adherence. Orforglipron is a novel once-daily oral non-peptide GLP-1 receptor agonist designed to provide comprehensive cardiometabolic risk reduction. PRISMA-compliant systematic review and…

  14. 14.
  15. 15.

    Li H, Yu G, Huang Q, Yang B, et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024 · PMID 38242040

    GLP-1 receptor agonists (GLP-1RAs) reduce glucagon and glycogen secretion, inhibit appetite and slow gastric empties and have recently been approved to treat obesity. To explore the safety and efficacy of GLP-1RAs in the treatment of obesity and clarify the optimal GLP-1RAs treatment regimen. PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18,…

  16. 16.

    Zhang S, Yu B, Xu J, Jin S, et al. · Diabetes technology & therapeutics · 2025 · PMID 39911047

    The objective of this study is to quantitatively compare the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adult patients with no diabetes and type 2 diabetes (T2D). PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase have been used as data sources from database inception to January 6, 2024. A total of 137 trials, encompassing 310 treatment arms, 17 GLP-1RAs, and 56,683 patients, were included in the analysis. The included trials were div…

  17. 17.

    Zhang Y, Zhang C, Gong X, Cheng P, et al. · European journal of medical research · 2026 · PMID 41582189

    To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes. A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases was conducted. Mean differences (MDs) were calculated as effect estimates for HR. Pairwise and network meta-analysis were conducted. Twelve articles were included. Pairwise meta-analysis showed significant association of increase compared with placebo in…

  18. 18.

    Hageen AW, Gadelmawla AF, Saleh AO, Abdallfatah A, et al. · Endocrinology, diabetes & metabolism · 2026 · PMID 42116665

    Orforglipron (OFG), an oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), has demonstrated significant weight loss and glycemic benefits in adults with or without type 2 diabetes (T2DM). However, its gastrointestinal (GI), hepatic and pancreatic safety profile has not been systematically evaluated. This network meta-analysis aimed to assess GI adverse events (AEs), hepatic and pancreatic outcomes, and enzyme changes across different OFG doses. A frequentist network meta-ana…

  19. 19.

    Hammad N, Ramadan AM, Nazmy A, Elazab A, et al. · Diabetes technology & therapeutics · 2026 · PMID 41640110

    Excess body weight and poor metabolic control remain major contributors to cardiometabolic disease, highlighting the need for effective therapeutic options. This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes. Searches were conducted across four databases through November 2025. Five randomized controlled trials (

  20. 20.

    Lu Y, Chen J, Guo Y, Ding H, et al. · Diabetes, obesity & metabolism · 2026 · PMID 41992023

    To characterize the cardiometabolic profiles of oral and subcutaneous glucagon-like peptide-1 (GLP-1) receptor mono-agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta-analysis (NMA). PubMed, Embase and CENTRAL were searched (January 2014-November 2025) for randomized controlled trials (RCTs) evaluating GLP-1 receptor mono-agonists (semaglutide, liraglutide and orforglipron) in adults with overweight or obesity. The primary outcome was the car…

  21. 21.

    Moiz A, Reynier P, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ, Filion KB. · 2026 · PMID 41808133

    <h4>Background</h4>Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited. This systematic review and network meta-analysis (NMA) will assess the comparative efficacy and safety of GLP-1 RAs and novel co-agonists for weight loss among adults without diabetes.<h4>Methods</h4>We will systematically search the PubMed, Ovid, and Cochrane CENTRAL databases to identify randomized controlled trials (RCTs) c…

  22. 22.

    Hegaz MG, Aboud MYA, Kamel AII, Naveed MA, et al. · BMC endocrine disorders · 2026 · PMID 42750018

    Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited by shorter follow-up and a predominance of non-diabetic populations. This meta-analysis aims to provide the most comprehensive head-to-head comparison between the two most commonly…

  23. 23.

    Hageen AW, Gadelmawla AF, Saleh AO, Mohamed MR, et al. · Endocrinology, diabetes & metabolism · 2026 · PMID 42487237

    Orforglipron (OFG), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RAs), showed potential benefits for type 2 diabetes mellitus (T2DM) and obesity. Its dose-response effects on body weight-related parameters and glycemic outcomes remain incompletely analysed. This network meta-analysis aims to address this gap across multiple doses of OFG (3, 12, 24, 36 and 45 mg) in adults with or without T2DM at 12, 26 and 36 weeks. PRISMA guidelines were followed in our study. Embase, Pu…

  24. 24.

    Alper A, Fagin A, Karthikeyan A, Karp A, et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 · PMID 42458197

    Orforglipron, an oral non-peptide GLP-1 receptor agonist, improves multiple cardiometabolic risk factors. However, prior modeling used only the 2013 Pooled Cohort Equations (PCE), which ignore body mass index (BMI), estimated glomerular filtration rate (eGFR), and hemoglobin A1c (HbA1c). We re-evaluated its cardiovascular benefit using the 2023 AHA PREVENT equations, which account for more nuanced variables. To compare the projected cardiovascular risk reduction from orforglipron when modeled us…

  25. 25.

    Nong K, Shi Q, Xie X, Wang Y, et al. · BMJ (Clinical research ed.) · 2026 · PMID 42419792

    To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. Medline, Embase, and Cochrane L…

  26. 26.

    Wu X, Yang Y, Cui X, Li X, et al. · Frontiers in pharmacology · 2026 · PMID 42394981

    This study systematically assessed the efficacy and safety of 15 incretin-based therapies (IBTs) for type 2 diabetes mellitus (T2DM), including mono- (GLP-1RA), dual- (GIP/GLP-1RA or GLP-1/GCGR), and triple- (GIP/GLP-1/GCGR) receptor agonists, and explored how dosage and treatment duration affect clinical outcomes to support individualized treatment decisions. A systematic review and Bayesian network meta-analysis were performed following PRISMA 2020 and PRISMA-NMA guidelines (PROSPERO: CRD42025…

  27. 27.

    Zou G, Yang C, Wu Q, Guo M, et al. · Diabetology & metabolic syndrome · 2026 · PMID 42983568

    To evaluate the effects of orforglipron and danuglipron on cardiovascular events and cardiometabolic risk markers in patients with type 2 diabetes mellitus (T2DM) and/or obesity. We searched PubMed, Embase, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov through May 5, 2026. Two authors independently performed study selection, data extraction, and quality assessment. Meta-analyses estimated pooled risk ratios (RRs), least-squares mean differences (LSMDs), and 95% confidence…

  28. 28.

    Emara A, Emara M, Mansour A, Elkholy MH, et al. · Diabetology & metabolic syndrome · 2026 · PMID 42363271

    Obesity and type 2 diabetes mellitus (T2DM) frequently coexist and markedly increase cardiometabolic risk. Orforglipron is a novel oral glucagon-like peptide-1 receptor agonist developed to improve adherence compared with injectable therapies. We performed a systematic review and meta-analysis to evaluate its efficacy and safety. PubMed, Scopus, Cochrane CENTRAL, and Web of Science were searched through January 2026 for randomized controlled trials (RCTs) comparing orforglipron with placebo in a…

Systematic Reviews

5
  1. 29.

    Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, et al. · Pharmacological reviews · 2025 · PMID 39952695

    The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food…

  2. 30.

    Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, et al. · Journal of Brown hospital medicine · 2025 · PMID 40191699

    Type 2 diabetes mellitus (T2DM) is a prevalent chronic condition with significant morbidity and mortality, largely due to its vascular complications. The emergence of novel pharmacological agents, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), has revolutionized T2DM management by addressing glycemic control and comorbidities such as cardiovascular and renal diseases. Traditionally, GLP-1RAs require subcutaneous injection, presenting challenges in patient adherence and limiti…

  3. 31.

    Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ · The lancet. Diabetes & endocrinology · 2024 · PMID 38723646

    Medications for obesity have been studied in various populations over the past three decades. We aimed to quantify the baseline demographic characteristics of BMI, sex, age, and race in randomised clinical trials (RCTs) across three decades to establish whether the population studied is representative of the global population affected by the disease. Clinical trials of 12 medications for obesity (ie, orlistat, naltrexone-bupropion, topiramate-phentermine, liraglutide, semaglutide, lorcaserin, si…

  4. 32.

    Takrori E, Peshin S, Singal S · Medicina (Kaunas, Lithuania) · 2025 · PMID 41303824

  5. 33.

    Paredes Yacaman GJ, Jiménez López AM, Cordova PR, Abad Cuenca SE, et al. · Cureus · 2026 · PMID 43011971

    Obesity is a chronic disease associated with increased cardiometabolic risk, reduced quality of life, and higher mortality. Although injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) have substantially improved weight management, the requirement for injections remains a limitation for many patients. Orforglipron is a novel nonpeptide oral GLP-1RA currently under investigation for the treatment of overweight, obesity, and type 2 diabetes mellitus (T2DM). This systematic review evalu…

Randomised Controlled Trials

18
  1. 34.

    Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, et al. · The New England journal of medicine · 2025 · PMID 40544435

    Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed. In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with d…

  2. 35.

    Wharton S, Aronne LJ, Stefanski A, Alfaris NF, et al. · The New England journal of medicine · 2025 · PMID 40960239

    Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary e…

  3. 36.

    Wharton S, Blevins T, Connery L, Rosenstock J, et al. · The New England journal of medicine · 2023 · PMID 37351564

    Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assi…

  4. 37.

    Pratt E, Ma X, Liu R, Robins D, et al. · Diabetes, obesity & metabolism · 2023 · PMID 37344954

    To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA) in healthy participants. This was a double-blind, placebo-controlled, Phase 1 study. Overtly healthy adults aged 18 to 65 years with body mass index of 20 to 40 kg/m Ninety-two participants enrolled and received at least one study drug dose (32 in Part A [mean age 43.4 years] and 60 in Part B…

  5. 38.

    Frias JP, Hsia S, Eyde S, Liu R, et al. · Lancet (London, England) · 2023 · PMID 37369232

    Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and safety of orforglipron versus placebo or dulaglutide in participants with type 2 diabetes. In this 26-week, phase 2, double-blind, randomised, multicentre study, participants were recruited from 45 centres (private clinics, hospitals, and research centers) in the USA, Hungary, Poland, and Slovakia. Adult participants aged 18 years or…

  6. 39.

    Pratt E, Ma X, Liu R, Robins D, et al. · Diabetes, obesity & metabolism · 2023 · PMID 37264711

    To report the results of a Phase 1b trial evaluating the safety, pharmacokinetics and pharmacodynamics of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). This was a double-blind, placebo-controlled Phase 1 study evaluating five different dosing regimens. The first group established that weekly dose escalation of the daily doses of orforglipron was generally well tolerated. This enabled a parallel-arm desig…

  7. 40.

    Horn DB, Ryan DH, Kis SG, Alves B, et al. · Lancet (London, England) · 2026 · PMID 41275875

    Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. This 72-week, phase 3, double-blind, placebo-controlled trial was conducted across 136 sites in ten countries. Participants with a BMI of 27 kg/m From June 5, 2023, to Feb 15, 2024, 2859 participants were screened, and 1613 (757 [46·9%] female) wer…

  8. 41.

    Wharton S, Rosenstock J, Konige M, Lin Y, et al. · Cardiovascular diabetology · 2025 · PMID 40481478

    Orforglipron, a novel oral, non-peptide glucagon like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving body weight reduction and glycemic control. However, its potential benefits in improving cardiovascular (CV) risk factors have yet to be determined. We assessed the effect of orforglipron in participants with type 2 diabetes (T2D) and/or overweight or obesity on blood pressure, lipid, and inflammatory biomarkers associated with risk for major adverse cardiovascular eve…

  9. 42.

    Rosenstock J, Robins DA, Duffin KL, Wilson JM, et al. · Diabetes, obesity & metabolism · 2025 · PMID 40808573

    These participant-level exploratory analyses evaluated the effects of orforglipron, a once-daily, orally administered non-peptide glucagon-like peptide-1 receptor agonist, versus dulaglutide and placebo, on β-cell function and insulin sensitivity biomarkers. Participants (N = 378) in this 26-week phase 2 study with inadequately controlled type 2 diabetes (T2D) were randomly assigned to orforglipron (3, 12, 24, 36, or 45 mg), dulaglutide (1.5 mg), or placebo. Treatment effects on β-cell function…

  10. 43.

    Rosenstock J, Yabe D, Cox D, Li J, et al. · Lancet (London, England) · 2026 · PMID 41765029

    Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individuals with type 2 diabetes inadequately controlled with metformin. In this 52-week, randomised, open-label, active-controlled, multicentre, multinational, phase 3 study, we enrolled adults (≥18 years) with type 2 diabetes inadequately controlled with metformin (≥15…

  11. 44.
  12. 45.

    Shahid M, Gandhi GY · Annals of internal medicine · 2025 · PMID 41052453

    GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].

  13. 46.

    Ohwaki K, Nakamura C, Nasu R, Takenouchi K, et al. · Journal of diabetes investigation · 2026 · PMID 41325139

    We aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of orforglipron in Japanese participants with type 2 diabetes. This was a double-blind, placebo-controlled, randomized, phase 1 study. In Part A, participants received single doses of orforglipron (2 or 3 mg) or placebo. In Part B, participants received multiple ascending doses of daily oral orforglipron (final target doses: 12, 24, and 45 mg) or placebo for 12 weeks. Parts A and B…

  14. 47.

    Klein KR, Wysham C, Tuttle KR, Davies MJ, et al. · Lancet (London, England) · 2026 · PMID 42815506

    Orforglipron is an oral, non-peptide GLP-1 receptor agonist. While some peptide GLP-1 receptor agonists have established cardiovascular benefit, the cardiovascular safety of non-peptide GLP-1 receptor agonists has not been studied. This study aimed to compare the effect of orforglipron with insulin glargine on the incidence of major adverse cardiovascular events in individuals with type 2 diabetes and obesity or overweight who are at increased risk for cardiovascular events. This event-driven, p…

  15. 48.

    Shinde S, Kahles F, Vasileva-Metodiev S, Griffin R, et al. · Diabetes, obesity & metabolism · 2026 · PMID 42750540

    To assess change in long-term predicted 10-year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D. This post hoc analysis used data from ATTAIN-1, a Phase 3 trial in adults (≥ 18 years) with obesity (BMI ≥ 30 kg/m At week 72, mean relative reduction from baseline (median baseline scores: 16.0%-17.3%) in T2D risk score was significantly greater with orforglipron than placebo (-48.6% to -59.4% vs. -10.5%; p < 0.0001; HR-r…

  16. 49.

    Yabe D, Shiraiwa T, Ugai H, Takeuchi M, et al. · The lancet. Diabetes & endocrinology · 2026 · PMID 42607698

    Orforglipron, an oral GLP-1 receptor agonist, requires further evaluation in east Asian populations with type 2 diabetes, given this group's distinct pathophysiological characteristics. This study aimed to assess orforglipron as add-on treatment to diet and exercise alone or to oral antihyperglycaemic medications in Japanese participants with type 2 diabetes. This multicentre, randomised, open-label phase 3 study was conducted in 40 medical research centres and hospitals in Japan. Adults with ty…

  17. 50.

    Welch M, Forst T, Jia W, Del Pino PO, et al. · Lancet (London, England) · 2026 · PMID 42259339

    Type 2 diabetes is a complex metabolic disorder often requiring combination therapy for optimal glycaemic control. This study assessed the efficacy and safety of orforglipron, an oral, non-peptide GLP-1 receptor agonist, versus dapagliflozin, an oral SGLT2 inhibitor, in participants with type 2 diabetes and inadequate glycaemic control with metformin. This 40-week, phase 3, multicentre, open-label (orforglipron dose-blinded), randomised study was conducted in 73 sites across six countries. The s…

  18. 51.

    Giorgino F, D'Souza S, Ludwig L, Kiyosue A, et al. · JAMA · 2026 · PMID 42251769

    The effects of orforglipron, an oral, nonpeptide glucagon-like peptide 1 receptor agonist, added to insulin glargine for treatment of type 2 diabetes have not been described. To assess efficacy and safety of orforglipron added to titrated insulin glargine in adults with type 2 diabetes and inadequate glycemic control. Randomized, double-blind, phase 3 study conducted at 72 sites across the US, Brazil, China, Japan, and Romania between November 10, 2023, and September 15, 2025, in adults with typ…

Clinical Trials

2
  1. 52.

    Morse BL, Bhattachar S, Ma X, Coutant DE, et al. · Clinical pharmacology in drug development · 2026 · PMID 40888509

    Orforglipron is a non-peptide, oral glucagon-like peptide 1 receptor agonist under development for glycemic control in adults with type 2 diabetes and weight management in people with obesity. Two phase 1, open-label studies evaluated the disposition and absolute bioavailability of orforglipron in healthy adults. Study A participants (N = 10) received a 1-mg orforglipron oral capsule while fasting and an intravenous dose of ∼21 µg of [14C]-orforglipron. Study B participants (N = 6) received an o…

  2. 53.

    Wharton S, Stefanski A, Chen J, Rao G, et al. · Diabetes, obesity & metabolism · 2026 · PMID 42338042

    Orforglipron is a novel small-molecule, once daily oral non-peptide GLP-1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed. Overall, 11 220 participants were included in this analysis (orforglipron N = 6920; pooled comparator [placebo, oral semaglutide, dapagliflozin, insulin glargine] N = 4300) for up to 104 weeks, including safety follow-up. Eligibility criteria for thes…

Trial Registrations (ClinicalTrials.gov)

54
  1. 54.

    NCT06704763 · Phase 1 · Completed · 2024

    Conditions: Healthy

  2. 55.

    NCT05936138 · Phase 1 · Completed · 2023

    Conditions: Renal Insufficiency, Healthy

  3. 56.

    NCT06993792 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight, Type 2 Diabetes

  4. 57.

    NCT06010004 · Phase 3 · Completed · 2023

    Conditions: Type 2 Diabetes

  5. 58.

    NCT06440980 · Phase 1 · Completed · 2024

    Conditions: Healthy, Obese, Overweight (+1)

  6. 59.

    NCT06085482 · Phase 1 · Completed · 2023

    Conditions: Healthy

  7. 60.

    NCT07202884 · Phase 3 · Recruiting · 2025

    Conditions: Urinary Incontinence,Stress

  8. 61.

    NCT07223593 · Phase 3 · Recruiting · 2025

    Conditions: Peripheral Arterial Disease

  9. 62.

    NCT06948435 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Hypertension, Overweight or Obesity

  10. 63.

    NCT05051566 · Phase 1 · Completed · 2021

    Conditions: Healthy

  11. 64.

    NCT05051579 · Phase 2 · Completed · 2021

    Conditions: Obesity, Overweight and Obesity

  12. 65.

    NCT06672939 · Phase 3 · Recruiting · 2024

    Conditions: Obesity, Overweight

  13. 66.

    NCT05869903 · Phase 3 · Active Not Recruiting · 2023

    Conditions: Obesity, Overweight, Overweight or Obesity

  14. 67.

    NCT07153471 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Osteoarthritis

  15. 68.
  16. 69.
  17. 70.

    NCT05048719 · Phase 2 · Completed · 2021

    Conditions: Type 2 Diabetes

  18. 71.

    NCT05882032 · Phase 1 · Completed · 2023

    Conditions: Healthy, Hepatic Insufficiency

  19. 72.
  20. 73.
  21. 74.

    NCT05341089 · Phase 1 · Completed · 2022

    Conditions: Healthy

  22. 75.

    NCT05931380 · Phase 3 · Completed · 2023

    Conditions: Obesity

  23. 76.

    NCT06649045 · Phase 3 · Completed · 2024

    Conditions: OSA, Overweight or Obesity

  24. 77.
  25. 78.

    NCT06972459 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight

  26. 79.

    NCT06672549 · Phase 3 · Recruiting · 2024

    Conditions: Obesity, Overweight

  27. 80.

    NCT05573230 · Phase 1 · Completed · 2022

    Conditions: Healthy

  28. 81.

    NCT06023095 · Phase 1 · Completed · 2023

    Conditions: Overweight, Obesity

  29. 82.
  30. 83.

    NCT05313802 · Phase 1 · Completed · 2022

    Conditions: Healthy, Obese

  31. 84.
  32. 85.

    NCT06186622 · Phase 1 · Completed · 2024

    Conditions: Healthy, Obese, Overweight

  33. 86.

    NCT04426474 · Phase 1 · Completed · 2020

    Conditions: Diabetes Mellitus, Type 2

  34. 87.

    NCT05803421 · Phase 3 · Completed · 2023

    Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity (+3)

  35. 88.

    NCT07241390 · Phase 3 · Recruiting · 2025

    Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

  36. 89.

    NCT06824051 · Phase 1 · Completed · 2025

    Conditions: Obesity, Overweight

  37. 90.

    NCT04680767 · Phase 1 · Completed · 2021

    Conditions: Healthy

  38. 91.

    NCT03929744 · Phase 1 · Completed · 2019

    Conditions: Healthy

  39. 92.

    NCT06972472 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight, Type 2 Diabetes

  40. 93.

    NCT05469126 · Phase 1 · Completed · 2022

    Conditions: Healthy

  41. 94.

    NCT05086445 · Phase 1 · Completed · 2021

    Conditions: Diabetes Mellitus, Type 2

  42. 95.

    NCT05110794 · Phase 1 · Completed · 2021

    Conditions: Healthy

  43. 96.

    NCT06370728 · Phase 1 · Completed · 2024

    Conditions: Healthy

  44. 97.
  45. 98.

    NCT05841238 · Phase 1 · Completed · 2023

    Conditions: Healthy, Obese

  46. 99.

    NCT05872620 · Phase 3 · Completed · 2023

    Conditions: Obesity, Overweight, Type 2 Diabetes

  47. 100.

    NCT07793019 · Phase 1 · Recruiting · 2026

    Conditions: Overweight, Healthy Participants, Obesity

  48. 101.
  49. 102.

    NCT07613307 · Phase 3 · Recruiting · 2026

    Conditions: Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders (+13)

  50. 103.

    NCT07729332 · Phase 4 · Not Yet Recruiting · 2026

    Conditions: Obesity

  51. 104.

    NCT07739537 · Phase 4 · Not Yet Recruiting · 2026

    Conditions: Diabete Type 2, Pharmacogenomic Drug Interaction

  52. 105.

    NCT07794579 · Phase 3 · Recruiting · 2026

    Conditions: Overweight, Prediabetic State, Prehypertension (+1)

  53. 106.

    NCT07790861 · Phase 3 · Not Yet Recruiting · 2026

    Conditions: Obesity, Overweight

  54. 107.

    NCT07668336 · Phase 3 · Recruiting · 2026

    Conditions: Diabetes Mellitus, Type 2

Reviews

25
  1. 108.

    Son JW, le Roux CW, Blüher M, Nauck MA, et al. · Endocrine reviews · 2026 · PMID 41054801

    The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through syn…

  2. 109.

    Gogineni P, Melson E, Papamargaritis D, Davies M · Expert opinion on pharmacotherapy · 2024 · PMID 38753454

    Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), gluca…

  3. 110.

    Panou T, Gouveri E, Popovic DS, Papanas N · Expert review of clinical pharmacology · 2025 · PMID 41275408

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes mellitus (T2DM) and obesity. An electronic search was conducted in Scopus, PubMed/MEDLINE, and Google Scholar databases. Orforglipron is a novel oral non-peptide GLP-1RA. In T2DM individuals, it has led to reductions in glycated hemoglobin (HbA Orforglipron is a promising treatment option for T2DM and overweight or obesity, in terms of glucose control and weight loss. The increased frequency…

  4. 111.

    Caruso I, Cignarelli A, Sorice GP, Perrini S, et al. · npj metabolic health and disease · 2024 · PMID 40604322

    Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and metabolic diseases (i.e. type 2 diabetes [T2D], metabolic dysfunction-associated steatotic liver disease [MASLD]). Lifestyle interventions represent the foundation of obesity treatment, yet an escalation to pharmacological and/or surgical interve…

  5. 112.

    Manoria PC · Cureus · 2025 · PMID 41393538

    Obesity is the most prevalent condition in high-income nations, primarily associated with increased risk of diabetes, cardiovascular disease (CVD), hypertension, and hyperlipidemia. Lifestyle modifications are a key determinant in non-pharmacological management that includes a combination of nutritional therapy, a low-calorie diet, and exercise. Earlier, anti-obesity drugs had been withdrawn from the market due to their safety profiles with cardiovascular and neuropsychiatric toxicity. The curre…

  6. 113.

    Kansakar U, Jankauskas SS, Pande S, Mone P, et al. · International journal of molecular sciences · 2026 · PMID 41683830

    Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence. Preclinical studies have demonstrated potent receptor engagement, favorable pharmacokinetics, and central nervous system activity. Phase 1-3 clinical trials have shown significant reductions in glycated hemoglobin (HbA1c), fasting and pos…

  7. 114.

    Al-Horani RA, Aliter KF, Aliter HF · Current diabetes reviews · 2024 · PMID 38275036

    Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabe…

  8. 115.

    Sidrak WR, Kalra S, Kalhan A · Indian journal of endocrinology and metabolism · 2024 · PMID 39676791

    Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have b…

  9. 116.

    Choe HJ, Cho YM · Endocrinology and metabolism (Seoul, Korea) · 2021 · PMID 33677922

    Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established cardiovascular disease or indicators of high risk. Until the advent of oral semaglutide, however, GLP-1 receptor agonists were available only in the form of subcutaneous injections. Aversion to needles, discomfort with self-injection, or skin pr…

  10. 117.

    Raza SS, Zakir Z, Hashmat A, Awan SK, et al. · Cureus · 2025 · PMID 41393574

    The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigational agents that are shaping clinical practice. We summarize mechanisms of action, pivotal efficacy data, safety profiles, indications, prescribing guidance, and key uncertainties. Approved long-term agents, orlistat, phentermine/topiramate, naltrexone/…

  11. 118.

    Lempesis IG, Dalamaga M · Metabolism open · 2026 · PMID 41948476

    Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscori…

  12. 119.

    Schnell O, Agarwal A, Azizi M, Ballwieser D, et al. · Cardiovascular diabetology · 2026 · PMID 42092956

    The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS…

  13. 120.

    Zaman W, Amin A · Expert opinion on pharmacotherapy · 2026 · PMID 42138103

    Obesity is a chronic, relapsing disease associated with substantial cardiometabolic morbidity and reduced quality of life. Although pharmacotherapy has advanced rapidly, current treatment options remain limited by tolerability concerns, access barriers, discontinuation, and reluctance toward injectable agents. Orforglipron, a once-daily oral glucagon-like peptide-1 receptor agonist, represents a potentially important step in expanding effective anti-obesity therapy. This review evaluates the eme…

  14. 121.

    Odeleye V, Singh N, Gautam S, Shannon E, et al. · Current cardiology reports · 2026 · PMID 41870800

    This article reviews the evidence for cardiovascular and renal risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM), based on randomized controlled trials, including emerging oral agents. Injectable GLP-1 RAs have consistently demonstrated reductions in major adverse cardiovascular events (MACE) and clinically relevant kidney outcomes, establishing their role in cardiorenal risk reduction. Oral semaglutide, the first approved oral GLP-1 RA,…

  15. 122.

    Jeon E, Lee KY, Kim KK · Journal of obesity & metabolic syndrome · 2023 · PMID 37349257

    Obesity is a prevalent global health issue affecting approximately half of the world's population. Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications. While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks. Given the global obesity…

  16. 123.

    Patel D · Cureus · 2026 · PMID 42153087

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected populations. Historically, GLP-1RA therapy has relied on injectable peptide agonists (e.g., liraglutide, semaglutide, dulaglutide, and exenatide), which mimic native incretin biology but require parenteral ad…

  17. 124.

    Habib MA, Sulieman AK, Albarq Z, Lua PL, et al. · Endocrine · 2026 · PMID 43037879

    To compare the safety and tolerability profiles of oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) against established injectable peptide GLP-1RAs, with emphasis on orforglipron, the most clinically advanced class member. This narrative review synthesises receptor pharmacology, Phase 3 clinical trial data, network meta-analyses, and regulatory prescribing-information documents for orforglipron; early-phase data for GSBR-1290 and CT-996 are considered separately as hypoth…

  18. 125.

    Alhazmi A, Le Roux CW · Drug design, development and therapy · 2026 · PMID 42871841

    Obesity is a major driver of Cardiovascular-Kidney-Metabolic (CKM) syndrome and contributes to the development of atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, chronic kidney disease, and type 2 diabetes. Historically, oral obesity pharmacotherapy was evaluated primarily according to weight loss efficacy. However, the emergence of the CKM framework has shifted therapeutic priorities toward modifying obesity related complications and improving long term clinical outc…

  19. 126.

    Shirley M · Drugs · 2026 · PMID 42479349

    Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly and Co. for use in long-term weight management and for the treatment of type 2 diabetes (T2D) among other indications. In April 2026, orforglipron received its first approval, in the USA, for use in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity or adults with overweight in the…

  20. 127.

    Wietholter JP, Terpening CM · The Annals of pharmacotherapy · 2026 · PMID 42760621

    To describe the properties of a newly approved oral glucagon-like peptide-1 receptor agonist for the treatment of obesity. A literature search of MEDLINE and SCOPUS was performed without date range exclusions using the search terms orforglipron and obesity. Additional articles were identified from review of clinical trial bibliographies and product monograph. Two phase 1 studies in healthy individuals and in patients with type 2 diabetes mellitus and 4 phase 2/3 clinical trials specifically eval…

  21. 128.

    Comisi JC · Clinical oral investigations · 2026 · PMID 42734711

    Obstructive sleep apnea (OSA) is associated with reproducible oral microbiome dysbiosis mediated by five simultaneous biological pathways: chronic intermittent hypoxia-driven immune dysregulation, obligate mouth breathing causing salivary desiccation, elevated salivary glucose promoting cariogenic biofilm proliferation, gastroesophageal reflux acid challenge, and hypothalamic-pituitary-adrenal axis activation suppressing mucosal immunity. The December 2024 FDA approval of tirzepatide for moderat…

  22. 129.

    Shah J, Luna-Ceron E, Payan-Schober F, Aimee Hechanova L, et al. · American journal of nephrology · 2026 · PMID 42715144

    Orforglipron, the first oral non-peptide GLP-1 receptor agonist, has a pharmacokinetic and formulation profile that may be theoretically attractive for patients with chronic kidney disease (CKD) including hepatic metabolism with minimal renal excretion and removal of potential barriers associated with current injectable and other oral formulations. We utilized a literature search utilizing PubMed/MEDLINE and ClinicalTrials.gov from their respective inceptions through May 2026 to synthesize a rev…

  23. 130.

    Cheng HE, Bonafede M, Shukla AP · Current atherosclerosis reports · 2026 · PMID 42696191

    This paper aims to review the current development of oral incretin-based therapies for treatment of overweight and obesity, and outline the efficacy of upcoming therapeutic candidates as well as their safety profiles. Clinical recommendations are provided regarding the role of oral incretin-based therapies for treatment of overweight and obesity. Until recently, almost all incretin-based therapies have been injectable formulations due to limitations in absorption and bioavailability. Recently, n…

  24. 131.

    Guo J, Chen H · Frontiers in pharmacology · 2026 · PMID 42729683

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes (T2D) and obesity, with injectable agents demonstrating significant cardiovascular (CV) risk reduction in pivotal trials including LEADER, SELECT, and SUMMIT. However, the reliance on injectable peptide formulations has constrained global accessibility and long-term adherence. The recent emergence of orally bioavailable, nonpeptide, small-molecule GLP-1 RAs-exemplified by orforglipron (Fou…

  25. 132.

    Castro-Gamboa J, Mora-Jiménez J, Arguedas-Chacón S, Zavaleta-Monestel E · Cureus · 2026 · PMID 42403733

    Orforglipron is an oral, nonpeptide, small-molecule glucagon-like peptide-1 receptor agonist developed for type 2 diabetes and obesity. This narrative review evaluates its comparative positioning among marketed GLP-1 receptor agonists by integrating structural, pharmacological, clinical, and practical evidence. A narrative literature review was conducted using PubMed/MEDLINE, Embase, Scopus, Web of Science, ClinicalTrials, official prescribing information, and citation tracking. The synthesis wa…

Research Articles

63
  1. 133.

    Kawai T, Sun B, Yoshino H, Feng D, et al. · Proceedings of the National Academy of Sciences of the United States of America · 2020 · PMID 33177239

    Glucagon-like peptide-1 receptor (GLP-1R) agonists are efficacious antidiabetic medications that work by enhancing glucose-dependent insulin secretion and improving energy balance. Currently approved GLP-1R agonists are peptide based, and it has proven difficult to obtain small-molecule activators possessing optimal pharmaceutical properties. We report the discovery and mechanism of action of LY3502970 (OWL833), a nonpeptide GLP-1R agonist. LY3502970 is a partial agonist, biased toward G protein…

  2. 134.

    Sloop KW, Cox AL, Wainscott DB, White A, et al. · Science translational medicine · 2024 · PMID 39693407

    Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competitio…

  3. 135.

    Ma X, Liu R, Pratt EJ, Benson CT, et al. · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024 · PMID 38402332

    We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B). Study A and study B were phase 1, randomized, crossover studies in healthy adults aged 18-65 years and 21-70 years, respectively. Participants received single (3 mg, study A) or multiple (16 mg, study B) oral doses of orforglipron under fasted and…

  4. 136.

    Pillai AA, Sharma AM, Krayem H, Frishman WH, et al. · Cardiology in review · 2025 · PMID 41398455

    The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration constraints of oral semaglutide, orforglipron offers a major convenience advantage: it is a small molecule with ~79% oral bioavailability that requires no food or water restrictions. Mechanistically, it act…

  5. 137.

    Santulli G · Cardiovascular diabetology. Endocrinology reports · 2025 · PMID 41053816

    Obesity remains a major global health challenge, driving type 2 diabetes, cardiovascular disease, and other complications. Despite effective lifestyle and surgical interventions, pharmacotherapy uptake has historically been limited. Injectable GLP-1 receptor agonists, including semaglutide and tirzepatide, have redefined expectations for medical obesity therapy, achieving 15–20% weight reductions in clinical trials. However, barriers such as injections, cost, and adherence limit their real-world…

  6. 138.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026 · PMID 42138709

  7. 139.

    Nauck MA, Horowitz M · Lancet (London, England) · 2023 · PMID 37369233

  8. 140.

    Krinsky D, Marcucci A, Mullally JA, Frishman WH · Cardiology in review · 2024 · PMID 39688941

    With the increasing prevalence of obesity and the advent of new and highly effective antiobesity medications, there is renewed interest in novel antiobesity pharmacotherapy. Currently, the most effective medications for obesity are injectable medicines. There is a need to develop equally efficacious oral drugs to increase availability to patients. Oral semaglutide was approved by the Food and Drug Administration for type 2 diabetes in 2019. Herein, we review the current literature regarding the…

  9. 141.

    Cong Z, Chen LN, Ma H, Zhou Q, et al. · Nature communications · 2021 · PMID 34145245

    The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonis…

  10. 142.

    Novikoff A, Müller TD · Med (New York, N.Y.) · 2025 · PMID 41389711

    The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinical trial, delivers meaningful reductions in body weight and improvements in metabolic health. This advancement moves beyond peptide-based injectables, paving the way for potent obesity therapies that are simpler, more affordable, and accessible to millions worldwide.

  11. 143.

    Aronne LJ, Horn DB, le Roux CW, Chao AM, et al. · Nature medicine · 2026 · PMID 42120723

    Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging. Orforglipron, a once-daily oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated weight loss efficacy, improvements in cardiometabolic risk factors, and safety generally similar to injectable GLP-1 receptor agonists. Here this double-blind, placebo-controlled trial randomized participants pre…

  12. 144.

    Xie X, Xuan X · The New England journal of medicine · 2025 · PMID 41337727

  13. 145.

    Rosenstock J, Cox D, Denning M · The New England journal of medicine · 2025 · PMID 41337728

  14. 146.

    Seetharaman R, Pandit S · Journal of basic and clinical physiology and pharmacology · 2023 · PMID 37581246

  15. 147.

    Seetharaman R, Pandit S · Journal of basic and clinical physiology and pharmacology · 2024 · PMID 38048046

  16. 148.

    Lau D · Annals of internal medicine · 2023 · PMID 37782925

    Wharton S, Blevins T, Connery L, et al; GZGI investigators.

  17. 149.

    Sonne N, Roque M, Zachariassen LF, Porsgaard T, et al. · EBioMedicine · 2026 · PMID 41547115

    Injectable peptide-based glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RAs) are effective treatments for obesity and diabetes but are limited by patient compliance and scalability challenges. In contrast, non-peptide small-molecule GLP1RAs offer the advantage of oral delivery but are relatively inactive at the rodent GLP1R, limiting their utility in preclinical pharmacodynamic studies. This study aimed to bridge the translational gap by engineering and thoroughly validating a humanised…

  18. 150.

    Pourkarim F, Entezari-Maleki T · The New England journal of medicine · 2023 · PMID 38091542

  19. 151.

    Vafeidou K, Koufakis T, Stavropoulos K, Zarfeiadou M, et al. · Expert review of endocrinology & metabolism · 2026 · PMID 41742335

  20. 152.

    Wharton S, Konig M · The New England journal of medicine · 2023 · PMID 38091543

  21. 153.

    Preston W · The New England journal of medicine · 2023 · PMID 38091541

  22. 154.

    Ma X, Li YG, Raha S, Sperry DC, et al. · Diabetes, obesity & metabolism · 2026 · PMID 41994902

    To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy. This phase 1, multicenter, open-label, multiple-dose, dose-escalation study was conducted in 429 healthy adults. Study participants received each orforglipron capsule and tablet dose strength once daily for 7 days in the fasted state at capsule doses of 1, 3, 6, 12, 24, or 36 mg and corresponding tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and…

  23. 155.

    Nagaoka T · The New England journal of medicine · 2025 · PMID 41337725

  24. 156.

    Jagarlapudi SP · The New England journal of medicine · 2025 · PMID 41337726

  25. 157.

    The Medical letter on drugs and therapeutics · 2026 · PMID 42139026

  26. 158.

    Imran R, Imran M, Roshan M · Acta diabetologica · 2026 · PMID 41984238

  27. 159.

    2006 · PMID 42044252

    No information is available on the use of orforglipron during breastfeeding. Until more information is available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

  28. 160.

    Șeremet OC, Pușcașu C, Andrei C, Nițulescu G, Zbârcea CE, Olaru OT. · 2025 · PMID 41303737

    Glucagon-like peptide-1 receptor (GLP-1R) agonists are injectable peptide-based therapies that have become a focal point in the medical community due to their significant therapeutic efficacy in type 2 diabetes and obesity treatment. Recent advancements in medicinal chemistry have enabled the development of small-molecule GLP-1R agonists, presenting advantages such as oral administration, improved patient adherence, and cost-effectiveness. These compounds demonstrate promising efficacy in enhanc…

  29. 161.

    Kim MK, Kim HS. · 2025 · PMID 39696983

    Obesity requires treatment as it is associated with health problems such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular diseases, and some cancers, which increase mortality rates. Achieving sufficient weight loss to reduce obesity-related diseases requires a variety of interventions, including comprehensive lifestyle modification of diet and exercise, change in behavior, anti-obesity medications, and surgery. To date, anti-obesity agents with various mechanisms of action have bee…

  30. 162.

    Tolkacheva EV, Salakhov TL, Saliev AY, Lebedeva ND, Krasnodubets AM, Smirnov EY, Silonov SA, Balakin KV, Chernyshov VV, Ivanov RA. · 2026 · PMID 41976172

    Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal endocrine L cells that activates the GLP-1 receptor (GLP-1R), leading to glucose-dependent insulin secretion and suppression of glucagon release. In recent years, GLP-1R agonists (GLP-1RAs) have become one of the leading therapeutic options for the treatment of type 2 diabetes mellitus; however, for a long time clinically approved GLP-1RAs were limited to peptide drugs unsuitable for oral administration. The discovery…

  31. 163.

    Alhazmi A, le Roux CW. · 2026 · PMID 41852477

  32. 164.

    Comte D. · 2025 · PMID 41340450

  33. 165.

    Ciarloni A, Salvio G, Bordoni M, Giacchetti G, Balercia G. · 2026 · PMID 42072319

    <b>Background/Objectives</b>: Obesity has a huge impact on global healthcare and economy. Consequently, the pharmaceutical industry has recently introduced novel anti-obesity drugs such as semaglutide and tirzepatide, which can yield remarkable weight reduction in patients, while also having significant cardiovascular benefits. <b>Methods</b>: Other weight-lowering medications are currently under investigation, and this narrative review provides an overview of the main novel drugs that are being…

  34. 166.
  35. 167.

    Look M, Bays H, Le Roux CW, Xavier NA, et al. · Obesity pillars · 2026 · PMID 42999545

    In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lit…

  36. 168.

    Almandoz JP, Miras AD, Blüher M, Orozco Del Pino P, et al. · Obesity pillars · 2026 · PMID 42936354

    Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to <30 kg/m This was a post-hoc analysis of the ATTAIN-1 trial (NCT05869903), a phase 3, randomized, double-blind, placebo-controlled trial in which adults without diabetes and with obesity or overweight were randomized 3:3:3:4 to once-daily oral orforglipron 5.5, 9…

  37. 169.

    Laffin L, Schlaich MP, Hall ME, Xie CC, et al. · American journal of preventive cardiology · 2026 · PMID 42830762

    Up to three-quarters of primary hypertension is epidemiologically attributed to excess adiposity. Incretin-based therapies are consistently associated with reduced blood pressure (BP) in clinical trials; however, no prior trial has investigated incretin-based therapies for hypertension treatment with BP as its primary efficacy outcome. ATTAIN-HYPERTENSION is a phase 3 master protocol directing two identical, randomized, placebo-controlled studies. Participants with BMI≥25kg/m ATTAIN-HYPERTENSION…

  38. 170.

    Plat A, Dennehy EB, Jouravskaya I, Stefanski A, et al. · Diabetes, obesity & metabolism · 2026 · PMID 43010686

    This post hoc analysis assessed the association between orforglipron and blood pressure in adults with obesity or overweight without (ATTAIN-1) and with Type 2 diabetes (T2D; ATTAIN-2). This study included ATTAIN-1 and ATTAIN-2 participants randomized to receive orforglipron (pooled doses) or placebo. A mixed model of repeated measures was used to assess changes in blood pressure across baseline subgroups at Week 72. The association between weight change and systolic blood pressure (SBP) was eva…

  39. 171.
  40. 172.

    Malhotra A, Gottlieb DJ, Woehrle H, Dennehy EB, et al. · JAMA · 2026 · PMID 43002161

    Obstructive sleep apnea (OSA) is a common disorder characterized by repeated upper airway collapse during sleep that is associated with reduced quality of life and increased incidence of cardiometabolic disease. To assess the effects of orforglipron on moderate to severe OSA in adults with obesity or overweight, compared with placebo. Two 52-week, phase 3, multicenter, double-blind, placebo-controlled randomized clinical trials were conducted at 66 sites in the US, Argentina, Brazil, China, Czec…

  41. 173.

    Htay T · Annals of internal medicine · 2026 · PMID 42970798

    GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].

  42. 174.

    Deng Y, Guo Z, Yu L, Zhang J, et al. · Biochemical pharmacology · 2026 · PMID 42508653

    Aortic aneurysm and dissection (AAD) are life-threatening vascular diseases for which effective pharmacological therapies remain limited. Smooth muscle cell phenotypic switching plays a central role in AAD development and progression. Orforglipron, a novel orally active non-peptide glucagon-like peptide-1 receptor agonist, has shown potential cardiovascular benefits; however, its role in AAD remains unclear. In this study, male B6 humanized GLP-1R mice were treated with orforglipron by oral gava…

  43. 175.

    Yokote K, Yamauchi T, Shingaki T, Chin R, et al. · The lancet. Diabetes & endocrinology · 2026 · PMID 42962687

    Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across phase 3 trials globally. We aimed to assess the efficacy and safety of orforglipron versus placebo for treating obesity disease in Japanese adults. ATTAIN-J was a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial conducted across 16 medical research centres and hospitals in Japan and included adults aged 18 y…

  44. 176.

    Giorgino F, Ludwig L, Denning M · JAMA · 2026 · PMID 42931748

  45. 177.

    Biswas S, Srivastava Y, Jadvani D · JAMA · 2026 · PMID 42931747

  46. 178.

    Sahu L, Nayak L, Tripathy A, Ramachandiran S, et al. · Omics : a journal of integrative biology · 2026 · PMID 42902597

    Incretin-based agents are transforming obesity pharmacotherapy, and orforglipron, the first oral non-peptide GLP-1 receptor agonist to complete phase 3 testing, invites direct comparison with the injectable agents semaglutide and tirzepatide. We integrated clinical trial evidence, including the direct head-to-head SURMOUNT-5 trial, independently verified molecular descriptors, a fully specified drug-target-disease network with permutation-tested hub significance, hypergeometric pathway enrichmen…

  47. 179.

    Kang YM, Nauck MA · Lancet (London, England) · 2026 · PMID 42880294

  48. 180.

    Boye K, Cutts K, Zhao Y, Steere E, et al. · The patient · 2026 · PMID 42888373

    There is an unmet need for effective and well-tolerated oral formulations of glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes. Orforglipron and oral semaglutide are two oral glucagon-like peptide 1 receptor agonists evaluated in the ACHIEVE-3 clinical trial (NCT06045221). These novel treatments have the means to achieve clinically meaningful glycemic control and weight reduction, which may result in substantial positive changes in patients' daily lives. The objecti…

  49. 181.

    Nauck MA, Horowitz M · The lancet. Diabetes & endocrinology · 2026 · PMID 42607699

  50. 182.

    Morse BL, Coutant DE, Ma X, Raha S, et al. · Clinical pharmacology and therapeutics · 2026 · PMID 42399716

    Orforglipron is an orally administered, small-molecule glucagon-like peptide-1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P-glycoprotein (P-gp); however, precipitants commonly used to define these mechanisms have not been fully characterized. The enzyme- and transporter-mediated DDI profile of orforglipron and that of CYP3A4/OATP1B/P-gp precipitants w…

  51. 183.
  52. 184.

    Horn DB, Shukla AP, Huang H, Twum E, et al. · Obesity pillars · 2026 · PMID 42577069

    Limited studies exist on incretin-based medications in older adults with obesity. Orforglipron, a novel small-molecule, non-peptide, oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), led to significant weight reduction in the Phase 3, randomized, double-blind ATTAIN-1 and ATTAIN-2 trials in participants with obesity or obesity and type 2 diabetes, respectively. This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy…

  53. 185.

    Mohammad A, Dashti M, Malik MDZ, Rajan R, et al. · International journal of biological macromolecules · 2026 · PMID 42437645

    Orforglipron (ORF), the first orally bioavailable non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist to complete Phase 3 clinical trials, binds a distinct extracellular vestibule pocket not engaged by peptide GLP-1RAs. How commonly GLP-1R single-nucleotide polymorphisms alter this unique binding mode at the molecular level remains uncharacterized. We employed an integrative computational framework that combines Boltz-2 deep learning co-folding for variant complex generation, 500 ns al…

  54. 186.

    Gadde KM, Talebloo J, Heymsfield SB · JAMA · 2026 · PMID 42251768

  55. 187.
  56. 188.

    Zhou Q, Li G, Wang MW · Trends in pharmacological sciences · 2026 · PMID 42420063

  57. 189.

    Malhotra A, Gottlieb DJ, Kundel V, Woehrle H, et al. · Contemporary clinical trials communications · 2026 · PMID 42383207

    Obstructive sleep apnea (OSA) is highly prevalent, yet current treatment remains limited. Poor adherence to positive airway pressure (PAP) and barriers associated with injectable therapies can limit potential therapeutic options for moderate-to-severe OSA. The SURMOUNT-OSA trials demonstrated that tirzepatide contributes to OSA severity improvements; however, the injectable mode of administration introduces barriers that may limit accessibility and long-term adherence. Orforglipron, a once daily…

  58. 190.

    Michalak W, Bøg M, Bendixen T, Chowdhury R, et al. · Diabetes, obesity & metabolism · 2026 · PMID 42225305

    This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs). Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods. Efficacy (percent…

  59. 191.

    Ramadurgum P, Shah J, Shah E, Palmer BF · Frontiers in pharmacology · 2026 · PMID 42582425

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to have significant nephroprotective effects, though the evidence lies almost exclusively with injectable formulations. Orforglipron is a novel oral, once-daily, non-peptide small-molecule GLP-1 RA with a distinct pharmacological mechanism compared to other GLP-1 RAs on the market. Unlike its predecessors, which bind an orthosteric peptide site, orforglipron binds the upper helical bundle of the same receptor. It acts as a G-p…

  60. 192.

    Li Y, Glotfelty EJ, Parekh P, Batsaikhan B, et al. · Cells · 2026 · PMID 42505410

    GLP-1 receptor (GLP-1R) agonists, widely used for diabetes and obesity management, have shown preclinical and clinical promise as potential therapeutics for neurological conditions. Until 2026, all U.S. Food and Drug Administration (FDA)-approved GLP-1 drugs were peptide-based, with most requiring daily or weekly subcutaneous injections. Despite their large size and low brain penetrance, several peptide-based GLP-1 drugs are in clinical trials for neurologic indications. Recently, the FDA approv…

  61. 193.

    Sheikh M, Fatima SH, Bilal Z, Amin JHJ · Annals of medicine and surgery (2012) · 2026 · PMID 42433749

  62. 194.

    Li M, Fang J, Qi G, Guo S, et al. · ACS medicinal chemistry letters · 2026 · PMID 42305200

    Orforglipron is a leading oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases; however, its oral exposure plateaus at higher doses, potentially limiting therapeutic efficacy. The solvent-exposed 4-fluoro-1-methylindazole branch of orforglipron was identified as a site amenable to modification for improving the physicochemical and pharmacokinetic properties. Systematic structure-activity relationship studies demonstrated that this region is highly tolerant…

  63. 195.

    Hoofnagle JH. · 2012 · PMID 42391415

    Orforglipron is an orally available, glucagon-like peptide-1 (GLP-1) receptor agonist that is approved as a weight loss agent. Rates of serum aminotransferase elevations during orforglipron therapy are no higher than with placebo and it has not been linked to instances of clinically apparent liver injury with symptoms or jaundice.

Preprints (not yet peer-reviewed)

2
  1. 196.

    Oztekin A, Turker S. · 2026

    GLP-1R is among the most heavily pursued targets in metabolic disease, but its natural agonist is a 30-residue peptide that must be injected. Two oral non-peptide agonists have reached late-stage trials. Cryo-EM studies have already shown that danuglipron and CHU-128, a close analogue of orforglipron, occupy the receptor differently, but not how either interface behaves over time. We ran 500 ns of unbiased all-atom molecular dynamics on GLP-1R bound to GLP-1, danuglipron (PF-06882961) and orforg…

  2. 197.

    Labate AM, Villari P, Cimino E, Giacomelli L, Oladeji OA, Agosti B. · 2026

    <h4>Background: </h4> /Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. <h4>Methods:</h4> We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protoc…

Curated sources on file

38
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.

Continue reading